Clinical studies have demonstrated that serum sEV miR-9-3p levels in patients with HCC are significantly higher than those in healthy people; miR-9-3p can induce HCC cells by down-regulating the expression of fibroblast growth factor 5 (FGF-5), inhibiting ERK1/2-mediated proliferation, and repressing apoptosis [124]. This evidence concerns the gene FGF5 and hepatocellular carcinoma.